Floatz logo

EMPEGFILGRASTIM

Gynecological Malignancies

Moscow Clinical Scientific Centerprotein_peptideDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

16 Active assets in the Gynecological Malignancies cohort.

Asset / SponsorPhaseRating
Carboplatin
Wenjun Cheng
Phase 3BB
Peg-Rhg-Csf
Peking University
Phase 4BB
Inno-206
Amgen
Phase 3BB
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
Sichuan Cancer Hospital and Research Institute
Phase 3BB
Pembrolizumab
Sheba Medical Center
Phase 2B

View all 30 →

Same molecule, other indications

EMPEGFILGRASTIM is also rated in:

Chemotherapy-induced NeutropeniaDormant
BB
Indicative ·
69 / 100
View asset →
Patients With Solid Tumours Who Receive Myelosupressive TherapyDormant
D
Indicative ·
30 / 100
View asset →
cancerDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →